Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic
P Di Ciaccio, G McCaughan, J Trotman… - Internal Medicine …, 2020 - Wiley Online Library
The COVID‐19 pandemic poses a unique challenge to the care of patients with
haematological malignancies. Viral pneumonia is known to cause disproportionately severe …
haematological malignancies. Viral pneumonia is known to cause disproportionately severe …
[HTML][HTML] Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned
A Isidori, L De Leval, U Gergis, P Musto… - Frontiers in oncology, 2020 - frontiersin.org
The COVID-19 pandemic has created unprecedented hurdles to the delivery of care to
patients with cancer. Patients with hematologic malignancies appear to have a greater risk …
patients with cancer. Patients with hematologic malignancies appear to have a greater risk …
[HTML][HTML] How I treat diffuse large B-cell lymphoma
Highlights•Several novel drugs have improved first-line and second-line treatment of DLBCL
in clinical practice.•De-escalation of low-risk patients reduces acute and late side …
in clinical practice.•De-escalation of low-risk patients reduces acute and late side …
[HTML][HTML] Mitotic poisons in research and medicine
J Škubník, M Jurášek, T Ruml, S Rimpelová - Molecules, 2020 - mdpi.com
Cancer is one of the greatest challenges of the modern medicine. Although much effort has
been made in the development of novel cancer therapeutics, it still remains one of the most …
been made in the development of novel cancer therapeutics, it still remains one of the most …
Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) encompasses a group of aggressive B-cell non-
Hodgkin lymphomas with striking genetic heterogeneity and variable clinical presentations …
Hodgkin lymphomas with striking genetic heterogeneity and variable clinical presentations …
Non‐Hodgkin's Lymphoma
AS Freedman, AS LaCasce - Holland‐Frei Cancer Medicine, 2016 - Wiley Online Library
Overview The malignant lymphomas are neoplastic transformations of cells that reside
predominantly within lymphoid tissues. Although Hodgkin and non‐Hodgkin lymphomas …
predominantly within lymphoid tissues. Although Hodgkin and non‐Hodgkin lymphomas …
[HTML][HTML] Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance
MR Berendsen, WBC Stevens, M van den Brand… - Cancers, 2020 - mdpi.com
Simple Summary Many patients with the aggressive cancer diffuse large B-cell lymphoma
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …
[HTML][HTML] Evolution of therapy for limited stage diffuse large B-cell lymphoma
AE Rojek, SM Smith - Blood Cancer Journal, 2022 - nature.com
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL),
with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment …
with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment …
Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the ΔSUVmax method
J Rekowski, A Hüttmann, C Schmitz… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The value of interim 18F-FDG PET/CT (iPET)–guided treatment decisions in patients with
diffuse large B-cell lymphoma (DLBCL) has been the subject of much debate. This …
diffuse large B-cell lymphoma (DLBCL) has been the subject of much debate. This …
[HTML][HTML] DLBCL 1L—what to expect beyond R-CHOP?
M Stegemann, S Denker, CA Schmitt - Cancers, 2022 - mdpi.com
Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
non-Hodgkin's lymphoma. About two-thirds of patients are cured by the first-line (1L) …
non-Hodgkin's lymphoma. About two-thirds of patients are cured by the first-line (1L) …